Immunotherapy and targeted therapy with chemoradiation for advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests combining two immunotherapy drugs (sintilimab and nimotuzumab) before standard chemoradiation for advanced head and neck squamous cell carcinoma that is EGFR-positive. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV head and neck cancer that is squamous cell and EGFR-positive.
- You have not received prior systemic therapy (like chemotherapy or immunotherapy) for this cancer.
- You are between 18 and 75 years old.
- You are in good physical condition (able to carry out daily activities without major difficulty).
- You have at least one measurable tumor (can be seen on scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a new combination therapy for people with advanced squamous non-small cell lung cancer. It adds sintilimab (an immunotherapy) and rh-endostatin (a drug that blocks blood supply to tumors) to standard chemotherapy, hoping to improve outcomes.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.